Nuveen Asset Management LLC Sells 74,212 Shares of Kura Oncology, Inc. (NASDAQ:KURA)

Nuveen Asset Management LLC cut its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 28.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 182,668 shares of the company's stock after selling 74,212 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.23% of Kura Oncology worth $1,591,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Millennium Management LLC increased its position in shares of Kura Oncology by 180.1% during the 4th quarter. Millennium Management LLC now owns 2,367,148 shares of the company's stock valued at $20,618,000 after purchasing an additional 1,521,954 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Kura Oncology by 8.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,031 shares of the company's stock worth $408,000 after acquiring an additional 3,617 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Kura Oncology in the 4th quarter worth about $8,518,000. Graham Capital Management L.P. purchased a new stake in Kura Oncology in the 4th quarter worth about $444,000. Finally, Deutsche Bank AG increased its holdings in Kura Oncology by 48.6% in the 4th quarter. Deutsche Bank AG now owns 64,623 shares of the company's stock worth $563,000 after acquiring an additional 21,135 shares during the last quarter.

Kura Oncology Price Performance

KURA stock traded up $0.12 during mid-day trading on Thursday, reaching $6.57. 853,702 shares of the company traded hands, compared to its average volume of 1,213,683. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $23.48. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The company has a market capitalization of $568.80 million, a P/E ratio of -2.78 and a beta of 0.50. The company has a fifty day moving average price of $6.07 and a 200-day moving average price of $7.82.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million during the quarter, compared to the consensus estimate of $39.08 million. As a group, analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

KURA has been the subject of several recent research reports. UBS Group decreased their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Wall Street Zen lowered Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. Barclays decreased their price objective on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Mizuho decreased their price objective on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, May 19th. Finally, Wedbush reissued an "outperform" rating and issued a $36.00 price objective on shares of Kura Oncology in a report on Tuesday, April 8th. Four investment analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $24.50.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.